TG Therapeutics, Inc. is a pharmaceutical company based in the United States, with an ESG risk rating score of 29.3, indicating a medium level of risk. Specializing in treatments for B-cell diseases, the company has secured FDA approval for BRIUMVI for the treatment of multiple sclerosis. They are also in the process of developing innovative treatments like TG-1701 and TG-1801 for various B-cell disorders, currently in phase 1 trials.